Genmab Reports Q3 DARZALEX Net Sales of $4.24 Billion
Genmab A/S (GMAB) recorded $4.239 billion in global third-quarter 2026 net trade sales for its key cancer drug DARZALEX. U.S. sales accounted for $2.528 billion of the total, while sales in the rest of the world reached $1.711 billion. Shares of the Danish biotechnology company traded up 0.76% to 2506 DKK following the release.
Because Genmab earns royalties on global DARZALEX transactions, these sales figures directly drive the company's top-line financial performance. Strong demand in the U.S. market underscores ongoing commercial traction in its primary geography, while international adoption continues to expand its global royalty base.
Investors will look for upcoming corporate updates detailing year-over-year growth rates, guidance changes, or potential shifts in royalty tiers tied to cumulative volume milestones.
Key points
- Global net trade sales for DARZALEX reached $4.239 billion in the third quarter of 2026.
- U.S. sales generated $2.528 billion, while rest-of-world sales totaled $1.711 billion.
- Genmab earns royalties on all reported worldwide sales of the therapy.
- Shares of Genmab A/S rose 0.76% to 2506 DKK following the update.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were Genmab's Q3 2026 DARZALEX sales?
Global net trade sales for DARZALEX reached $4.239 billion in Q3 2026, with $2.528 billion coming from the U.S. and $1.711 billion from the rest of the world.
How does DARZALEX revenue affect Genmab?
Genmab receives royalty payments on global DARZALEX sales, making these results a primary driver of the company's top-line revenue.
How did Genmab stock react to the Q3 sales report?
Genmab A/S shares traded at 2506 DKK, up 0.76% for the day.